Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients

Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications

(2010) S. M. Keefe et al.   CLINICAL CANCER RESEARCH

Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination

(2010) Randa M. Abdulrahman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients

(2009) Toru Mukohara et al.   CANCER SCIENCE

Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma

(2009) Dale R Shepard et al.   Expert Review of Anticancer Therapy

Sunitinib-Induced Hemoglobin Changes Are Related to the Dosing Schedule

(2009) Astrid A.M. van der Veldt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

(2009) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

(2009) Joan H. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy

(2009) Francesco Torino et al.   Nature Reviews Clinical Oncology

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation

(2009) Hideaki Miyake et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib

(2008) Doru T. Alexandrescu et al.   JOURNAL OF CLINICAL ONCOLOGY

Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell Carcinoma

(2008) Ingrid Alexandre et al.   JOURNAL OF CLINICAL ONCOLOGY

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

(2007) I. Tamaskar et al.   ANNALS OF ONCOLOGY